InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.515 0.09 (21.18%)+
Announcement
Release
11 Jun 2026 8:38AM
Price at Release
$0.425
Full Release
download
Summary
LTR Pharma Limited has executed a binding term sheet with Strive Specialties Inc. to establish exclusive US pharmacy fulfillment rights for ROXUS®, an intranasal treatment for erectile dysfunction. This agreement marks a critical milestone in LTR Pharma’s US commercialization strategy, providing access to an extensive pharmacy infrastructure and healthcare network. The term sheet includes exclusivity and confidentiality provisions and aims to support a multi-channel strategy to reach US consumers through telehealth and healthcare provider networks. LTR Pharma is the product owner and supplier, while Strive Pharmacy facilitates pharmacy fulfillment, enhancing patient access and reducing launch risk. Agreements are being finalized to commence commercial launch activities.
Key Points
  • Binding term sheet with Strive Specialties Inc. for exclusive US pharmacy fulfillment rights for ROXUS®.
  • Represents a key milestone in LTR Pharma's US commercialization strategy.
  • ROXUS® to be distributed via a multi-channel strategy including telehealth.
  • LTR Pharma holds product ownership and supply rights.
  • Strive Pharmacy provides the fulfillment infrastructure.
  • Agreement includes exclusivity, confidentiality, and service-level provisions.
  • Two-year initial term with annual auto-renewal.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.